We used a prototype time-resolved fluorescence lifetime microplate reader to carry out a high-throughput screen designed to identify compounds that interact with the sarcoplasmic reticulum calcium ATPase (SERCA). SERCA is essential for the Ca homeostasis in many cell types. Insufficient SERCA activity leads to cardiovascular disease, muscular dystrophy, skin disease, and diabetes. Our goal is to discover activators of SERCA that can be developed into drugs to treat diseases in which Ca transport is deficient. The fluorescence lifetime plate reader was made possible by our recent development of fast time-resolved fluorescence by direct waveform recording, which achieves 105 higher throughput than the conventional single-photon counting technology. using this plate reader, we detected fluorescence resonance energy transfer (FRET) between IAEDANS-labeled SERCA and nucleotide analog TNPADP in native sarcoplasmic reticulum membranes. This assay was designed to detect compounds that interact with SERCA and modify either the enzyme's structure or the binding affinity of TNP-ADP. Initial hit compounds were further analyzed in functional assays. Upon screening a small (1300 compound) library, we determined that the time-resolved microplate reader has at least 10x higher precision than a conventional intensity-based microplate reader, raising the quality index (z') of our assay from marginal, in the intensity reader, to excellent. A 384-well plate is read with high precision in 2 min, which allows screening of thousands of compounds/day. An important advantage of the time-resolved fluorescence measurement is that it provides detailed structural information, thus enabling discovery of multiple classes of compounds during the primary screen. University of Minnesota, Minneapolis, MN, USA, 2 Loyola University, Chicago, IL, USA. We are using in-cell FRET methods (Photobleaching, FLIM, time-resolved FRET in a plate reader) to study the relationships among structure, dynamics, and function of the sarcoplasmic reticulum Ca-ATPase (SERCA) and its cardiac regulator phospholamban (PLB), with the goal of designing activators of SERCA for treatment of heart failure (HF) and muscular dystrophy (MD). Ca 2þ drives muscle contraction, and relaxation is accomplished by the sequestration of Ca 2þ by the sarcoplasmic reticulum Ca-ATPase (SERCA), which is inhibited by phospholamban at submicromolar [Ca 2þ ] in cardiac muscle. SERCA activity is frequently reduced in HF, and many current therapeutic strategies aim to increase cardiac Ca 2þ cycling activity. We are designing LOF-PLB mutants (PLB M ) that can compete with WT-PLB (PLB W ) and thus relieve SERCA inhibition. Our ideal mutant is partial loss-of-function, binds tightly to SERCA2a, and remains phosphorylatable via b-adrenergic pathways. The effects of PLB M on Ca-ATPase activity and FRET are measured to determine the mutant's ability to compete with PLB W , both physically and functionally. Optimal LOF mutants are being tested in a rat model of heart failure. In addition to this SERCA-PLB FRET competition assay, we are using SERCA2a labelled with two different fluorescent probes (GFP and RFP) to screen for small molecule activators of SERCA in living cells. Timeresolved FRET measurements of RFP-GFP-SERCA2a in 96-or 384-well plates have shown the extraordinary precision and sensitivity necessary to probe SERCA's structure-function relationship. New drug screening efforts are active and small molecules from previous screens are being developed as promising drugs for HF therapy (collaboration with Celladon, Inc.). Many of these drugs are direct SERCA activators and are being investigated for their ability to rescue the muscular dystrophy phenotype in dystrophic mice. We have used site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy to investigate the effects of Ser16 phosphorylation on phospholamban's interaction with the sarcoplasmic reticulum Ca-ATPase (SERCA). Muscle contraction is signaled by the release of Ca from the sarcoplasmic reticulum (SR), while SERCA mediates muscle relaxation by actively pumping Ca back into the SR lumen. Cardiac SERCA is regulated by phospholamban (PLB), a single-pass transmembrane protein that inhibits the Ca pump unless phosphorylated at Ser16. We have shown that Ser16 phosphorylation does not dissociate PLB from SERCA to relieve inhibition, but instead induces a structural change in PLB's transmembrane (TM) helix that restores SERCA Ca sensitivity. To characterize this change, we have attached spin labels along the TM helix and performed EPR accessibility measurements to determine the effects of Ser16 phosphorylation on TM helix topology within the regulatory complex. Our results show that upon phosphorylation, the TM helix undergoes a vertical shift that could break inhibitory interactions between SERCA and PLB. Complementary ongoing studies employ these spin-labeled PLB constructs to determine changes in (a) the orientation of PLB and (b) distances to probes on SERCA, with the goal of obtaining a detailed structural model for the regulatory transitions within the SERCA-PLB complex. We have used electron paramagnetic resonance (EPR) to probe the structural dynamics of the integral membrane protein phospholamban (PLB), as a function of phosphorylation and addition of its regulatory target, the sarcoplasmic reticulum calcium ATPase (SERCA). We found previously that PLB remains bound to SERCA after phosphorylation, suggesting that a structural transition within the SERCA-PLB complex is responsible for relief of inhibition. Our current goal is to elucidate this mechanism through orientation and accessibility EPR, in order to support rational design of therapies to improve calcium transport in muscle cells. We used the monomeric mutant AFA-PLB, with the rigid electron spin label TOAC incorporated within the transmembrane domain, and reconstituted the protein in lipid bicelles and vesicles. EPR showed that the accessibilities of PLB spin labels to paramagnetic relaxation agents changed upon phosphorylation, indicating vertical (parallel to the membrane normal) movement of PLB. EPR on aligned bicelles showed that PLB changes its tilt relative to the membrane upon phosphorylation. Results will also be reported on structural changes in the presence of SERCA. This work was funded by grants from NIH (R01 GM27906 and T32 AR007612).
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University of Minnesota, Minneapolis, MN, USA, 2 Loyola University, Chicago, IL, USA. We are using in-cell FRET methods (Photobleaching, FLIM, time-resolved FRET in a plate reader) to study the relationships among structure, dynamics, and function of the sarcoplasmic reticulum Ca-ATPase (SERCA) and its cardiac regulator phospholamban (PLB), with the goal of designing activators of SERCA for treatment of heart failure (HF) and muscular dystrophy (MD). Ca 2þ drives muscle contraction, and relaxation is accomplished by the sequestration of Ca 2þ by the sarcoplasmic reticulum Ca-ATPase (SERCA), which is inhibited by phospholamban at submicromolar [Ca 2þ ] in cardiac muscle. SERCA activity is frequently reduced in HF, and many current therapeutic strategies aim to increase cardiac Ca 2þ cycling activity. We are designing LOF-PLB mutants (PLB M ) that can compete with WT-PLB (PLB W ) and thus relieve SERCA inhibition. Our ideal mutant is partial loss-of-function, binds tightly to SERCA2a, and remains phosphorylatable via b-adrenergic pathways. The effects of PLB M on Ca-ATPase activity and FRET are measured to determine the mutant's ability to compete with PLB W , both physically and functionally. Optimal LOF mutants are being tested in a rat model of heart failure. In addition to this SERCA-PLB FRET competition assay, we are using SERCA2a labelled with two different fluorescent probes (GFP and RFP) to screen for small molecule activators of SERCA in living cells. Timeresolved FRET measurements of RFP-GFP-SERCA2a in 96-or 384-well plates have shown the extraordinary precision and sensitivity necessary to probe SERCA's structure-function relationship. New drug screening efforts are active and small molecules from previous screens are being developed as promising drugs for HF therapy (collaboration with Celladon, Inc.). Many of these drugs are direct SERCA activators and are being investigated for their ability to rescue the muscular dystrophy phenotype in dystrophic mice. We have used site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy to investigate the effects of Ser16 phosphorylation on phospholamban's interaction with the sarcoplasmic reticulum Ca-ATPase (SERCA). Muscle contraction is signaled by the release of Ca from the sarcoplasmic reticulum (SR), while SERCA mediates muscle relaxation by actively pumping Ca back into the SR lumen. Cardiac SERCA is regulated by phospholamban (PLB), a single-pass transmembrane protein that inhibits the Ca pump unless phosphorylated at Ser16. We have shown that Ser16 phosphorylation does not dissociate PLB from SERCA to relieve inhibition, but instead induces a structural change in PLB's transmembrane (TM) helix that restores SERCA Ca sensitivity. To characterize this change, we have attached spin labels along the TM helix and performed EPR accessibility measurements to determine the effects of Ser16 phosphorylation on TM helix topology within the regulatory complex. Our results show that upon phosphorylation, the TM helix undergoes a vertical shift that could break inhibitory interactions between SERCA and PLB. Complementary ongoing studies employ these spin-labeled PLB constructs to determine changes in (a) the orientation of PLB and (b) distances to probes on SERCA, with the goal of obtaining a detailed structural model for the regulatory transitions within the SERCA-PLB complex. We have used electron paramagnetic resonance (EPR) to probe the structural dynamics of the integral membrane protein phospholamban (PLB), as a function of phosphorylation and addition of its regulatory target, the sarcoplasmic reticulum calcium ATPase (SERCA). We found previously that PLB remains bound to SERCA after phosphorylation, suggesting that a structural transition within the SERCA-PLB complex is responsible for relief of inhibition. Our current goal is to elucidate this mechanism through orientation and accessibility EPR, in order to support rational design of therapies to improve calcium transport in muscle cells. We used the monomeric mutant AFA-PLB, with the rigid electron spin label TOAC incorporated within the transmembrane domain, and reconstituted the protein in lipid bicelles and vesicles. EPR showed that the accessibilities of PLB spin labels to paramagnetic relaxation agents changed upon phosphorylation, indicating vertical (parallel to the membrane normal) movement of PLB. EPR on aligned bicelles showed that PLB changes its tilt relative to the membrane upon phosphorylation. Results will also be reported on structural changes in the presence of SERCA. This work was funded by grants from NIH (R01 GM27906 and T32 AR007612).
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Probing Cardiac Membrane Proteins with Fluorescence Resonance Energy Transfer Xiaoqiong Dong, Ji Li, Christine B. Karim, David D. Thomas. University of Minnesota, Minneapolis, MN, USA. We have used time-resolved fluorescence resonance energy transfer (TR-FRET) to study the structural basis of regulation of sarcoplasmic reticulum Ca 2þ ATPase (SERCA) by a single-pass transmembrane protein, phospholamban (PLB). The most prominent feature of heart failure is calcium mishandling, which is largely due to impaired activity of sarcoplasmic reticulum calcium ATPase (SERCA), which actively transports Ca 2þ from cytosol into the SR to relax the muscle. Unphosphorylated phospholamban inhibits SERCA by decreasing its apparent Ca 2þ affinity. This inhibition can be relieved by either micromolar Ca 2þ or by phosphorylation of PLB. The structural basis for relief of inhibition remains controversial. Cross-linking studies support the canonical dissociation model. However, recent EPR, NMR and FRET studies support the subunit model, in which subtle structural rearrangements are required to relieve the inhibition. The goal of this study is to elucidate the structural rearrangements during relief of inhibition. Previous EPR and NMR studies found that the cytoplasmic domain of PLB exists in a dynamic equilibrium between T and R states. We have used time-resolved fluorescence resonance energy transfer (TR-FRET) to probe the complex directly by measuring the distances between SERCA (C674) and a series of positions on PLB in co-reconstituted vesicles. We found that the distances between SERCA and the cytoplasmic domain of PLB are best fitted with two Gaussian distance distributions, suggesting that the cytoplasmic domain of bound PLB exists in two states. Results will be reported on the effects of perturbations in this system which are known to relieve inhibition, including PLB phosphorylation, PLB mutation, and calcium binding to SERCA. We conclude that the function of the SERCA-PLB complex depends primarily on the structural equilibrium between two principal structural states of the complex. 
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þ -ATPase within the a subunit. To gain further insights into the ouabain binding mechanism, we used a spectroscopic approach (LRET) to measure distances between a genetically encoded lanthanide binding tag (LBT; that binds Tb 3þ with high affinity) and a cysteine-reactive fluorescent compound (Bodipy). We created energy transfer pairs by encoding LBTs in three of the external loops of the a subunit, connecting transmembrane helices (TM) 1-2, 3-4 and 9-10, and cysteines substituted in different positions of the b subunit. These constructs were expressed in Xenopus oocytes. Distances were estimated using the luminescence decays of donor only and sensitized emission, upon excitation with a 9-ns pulse at 266 nm. In each oocyte expressing a LBT-(Tb 3þ )-Bodipy pair, distance determinations were made in the absence, and in the presence of ouabain. The results suggest that upon binding of ouabain, all external loops move as if the extracellular end of the permeation pathway of the pump opens up in the presence of ouabain. Further, no significant movements of the b subunit were detected in the LRET experiments. With these determinations, molecular modeling of the LBT-(Tb 3þ )-Bodipy pair constructs were performed to build models corresponding to pump's conformations in the absence and presence of ouabain. These models suggest partial opening of the TM helices on the extracellular side. These changes will allow access of ouabain to its binding site, deep inside the permeation pathway. Supported by U54GM087519, GM030376 and NIH/NINDS Intramural Program. ATPase with high similarity to the plasma membrane ATPases (PMCA), a type IIb P-type ATPase from higher eukaryotes. There is no X-ray structures of any PMCA's determined, they are known to be less stabile in comparison with the sarco(endo)plasmic reticulum Ca 2þ -ATPases (SERCA) and also often require additional soluble factors to function, like the necessity of Calmodulin to the PMCA [2] . We have determined the structure to 2.7 Å resolution initial structural comparison indicate a similar fold to SERCA, however with significantly reduced loop regions. A comparative bioinformatics study will be presented based on Lmo0818 that reveal how the pumps are could act as receptors in prokaryotic membrane systems as compared to ion recognition and receptor function found in the Naþ,Kþ -ATPase [3].
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An Arginine-Agmatine Antiporter Optimized for Extreme Acid Resistance in Enteric Bacteria Ming-Feng Tsai, Christopher Miller. Brandeis University, waltham, MA, USA. Enteric bacteria such as E. coli and Salmonella species can maintain cytoplasmic pH in the extremely acidic gastric environments by consuming intracellular protons for arginine decarboxylation. This reaction is kept energetically favorable by an APC (amino-acid-polyamine-organocation) family antiporter AdiC, which imports arginine while pumping out the decarboxylated product agmatine in a 1:1 exchange stoichiometry. To characterize AdiC's transport behavior in extreme acid conditions, we developed an oriented reconstituted liposome system able to hold a 3-unit transmembrane pH gradient. Our work reveals two unique functional properties by which AdiC maximizes its effectiveness in conferring acid resistance. First, AdiC possesses a pH-sensing mechanism that permits maximal transport activity only under intra-and extracellular pH conditions of bacteria experiencing strong acid stress (i.e., outside pH 2-3; inside pH 4.5-5.5). Second, we demonstrate that AdiC mainly catalyzes electropositive exchange between extracellular arginine (50% Arg þ , 50% Arg2 þ , pH2.2) and cytoplasmic agmatine (Agm2 þ , pH5.5) -the exchange is strongly inhibited by the imposition of negative membrane potentials. Thus, at gastric pH, AdiC selectively imports the less common Arg þ against the useless a-carboxyl protonated Arg2 þ , whose deprotonation upon entry into the cytosol would cancel out the proton-removing effect of arginine decarboxylation. We are currently investigating the underlying mechanisms for this second feature of AdiC. Preliminary results from testing various arginine analogues suggest that AdiC differentiates Arg þ and Arg2 þ based on their difference in valence number rather than the protonation status in the a-carboxyl. Rhizoferrin is a simple but efficient siderophore and is potentially important for medical applications. The aim of this investigation is to determine the molecular structure of free rhizoferrin as well as its Fe 3þ complexes, and to understand the mechanisms of cation (Fe 3þ )-binding specificity of rhizoferrin, using first-principle methods. The optimized molecular structures, and the calculated Nuclear Magnetic Resonance properties, such as chemical shifts for 13 C and 1 H and indirect dipole dipolecouplings for 1 H, will be presented and compared with the experimental data. The nuclear quadrupole interaction parameters will be discussed as an attempt to understand the charge distribution and electric field gradient. Possible influence of deprotonation of citrate carboxylate groups on Fe 3þ -rhizoferrin complex formation will be discussed. This is, to the best of our knowledge, the first theoretical study of rhizoferrin and its metal complexes, and it provides a critical insight and guidance to the structural basis of metal chelation by rhizoferrin.
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Supported Membrane System to Evaluate the Ion-Pump Activity of Reconstituted Proteins under an Optical Microscope Jyunan Ki. The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Supported membrane is the experimental platform in which a lipid bilayer is tethered on a solid surface. Owing to the mechanical stability, it allows us to investigate physicochemical properties of membranes and also membrane proteins reconstituted in it. In this study, we developed a novel supported membrane system that enables to measure the ion-pump activity of membrane proteins under an optical microscope. As a model ion pump, we reconstituted FoF1-ATP synthase (FoF1) in liposomes. To prepare the supported membrane on a cover slip, we deposited the liposome on the cover slip and dehydrated them. Sequentially we rehydrated it with the buffer. This is relatively simple way to generate an artificial bilayer under optical microscope. In the rehydration buffer, we contained a pH indicator fluorescent dye (pHrodo) and Caged-ATP. By introducing the evanescent illumination of 405 nm light for uncaging of ATP from the bottom of the glass surface, ATP was supplied only in the illumination area. The local pH of the membrane-surface space was monitored with the fluorescent signal of pHrodo excited with the evanescent illumination of 532 nm. Only after the illumination for uncaging, the intensity of pHrodo 300a
